JMP Group Announces Addition of Reni Benjamin to Equity Research Department

SAN FRANCISCO–(BUSINESS WIRE)–JMP Group LLC (NYSE: JMP), an investment banking and alternative asset management firm, announced today that Reni Benjamin, Ph.D. has joined JMP Securities as a managing director and equity research analyst covering biotechnology. Based in the firm’s New York office, Dr. Benjamin will focus on the oncology sector.

“Ren will immediately be a key contributor to our healthcare franchise,” said Thomas Wright, director of equities at JMP Securities. “He is a well-recognized and well-respected analyst whose arrival renews JMP’s commitment to the oncology space—an area of tremendous importance to life sciences investors. Ren’s expertise and ability to distill complex information into actionable ideas will make him a valuable resource for our firm’s institutional and corporate clients alike.”

Dr. Benjamin joins JMP Securities from Raymond James, where he was a managing director and senior research analyst. Dr. Benjamin was previously a managing director at H.C. Wainwright & Co. and Rodman & Renshaw, after starting his career in biotechnology research at Needham & Company. Dr. Benjamin holds a Ph.D. in biochemistry and molecular genetics from the University of Alabama at Birmingham and a B.S. in biology from Allegheny College. He is a past member of the UAB School of Health Professions Dean’s Advisory Board and currently serves on the advisory board of Phacilitate Cell & Gene Therapy.